Pharmacokinetics of imatinib when administered alone and with hypericum perforatum in 10 subjects
Period . | Tmax, h . | Cmax,*μg/mL . | Half-life,*h . | AUC0-∞,*μg × h/mL . | Clast,*μg/mL . | Protein binding, % . |
|---|---|---|---|---|---|---|
| Imatinib | 2.5 (1-4) | 1.80 (0.88-2.6) | 13.5 (10.8-18.1) | 28.9 (13.4-36.7) | 0.11 (0.05-0.17) | 95.0 (90.3-97.7) |
| Imatinib + hypericum perforatum | 2.5 (1-8) | 1.28 (0.92-2.0) | 10.7 (9.1-13.5) | 19.7 (10.7-25.0) | 0.05 (0.03-0.12) | 95.1 (90.9-97.3) |
Period . | Tmax, h . | Cmax,*μg/mL . | Half-life,*h . | AUC0-∞,*μg × h/mL . | Clast,*μg/mL . | Protein binding, % . |
|---|---|---|---|---|---|---|
| Imatinib | 2.5 (1-4) | 1.80 (0.88-2.6) | 13.5 (10.8-18.1) | 28.9 (13.4-36.7) | 0.11 (0.05-0.17) | 95.0 (90.3-97.7) |
| Imatinib + hypericum perforatum | 2.5 (1-8) | 1.28 (0.92-2.0) | 10.7 (9.1-13.5) | 19.7 (10.7-25.0) | 0.05 (0.03-0.12) | 95.1 (90.9-97.3) |
Data presented as median (range). Tmax indicates time of Cmax; Clast, imatinib concentration at 48 hours.
P < .005 by paired t test on logarithmically transformed data.